| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US6727286 | CUMBERLAND PHARMS | Pharmaceutical composition of 2-(4-isobutylphenyl) propionic acid |
Nov, 2021
(2 years ago) | |
| US9649284 | CUMBERLAND PHARMS | Treating critically ill patients with intravenous ibuprofen |
Sep, 2029
(5 years from now) | |
| US9114068 | CUMBERLAND PHARMS | Treating patients with intravenous ibuprofen |
Sep, 2029
(5 years from now) | |
| US8735452 | CUMBERLAND PHARMS | Treating patients with intravenous ibuprofen |
Sep, 2029
(5 years from now) | |
| US8871810 | CUMBERLAND PHARMS | Treating critically ill patients with intravenous ibuprofen |
Sep, 2029
(5 years from now) | |
| US9295639 | CUMBERLAND PHARMS | Treating critically ill patients with intravenous ibuprofen |
Sep, 2029
(5 years from now) | |
| US9138404 | CUMBERLAND PHARMS | Treating critically ill patients with intravenous ibuprofen |
Sep, 2029
(5 years from now) | |
| US9012508 | CUMBERLAND PHARMS | Administration of intravenous ibuprofen |
Sep, 2030
(6 years from now) | |
| US9072710 | CUMBERLAND PHARMS | Injectable ibuprofen formulation |
Mar, 2032
(7 years from now) | |
| US9072661 | CUMBERLAND PHARMS | Injectable ibuprofen formulation |
Mar, 2032
(7 years from now) | |
| US11806400 | CUMBERLAND PHARMS | Injectable ibuprofen formulation |
Mar, 2032
(7 years from now) | |
Caldolor is owned by Cumberland Pharms.
Caldolor contains Ibuprofen.
Caldolor has a total of 11 drug patents out of which 1 drug patent has expired.
Expired drug patents of Caldolor are:
- US6727286
Caldolor was authorised for market use on 11 June, 2009.
Caldolor is available in solution;intravenous dosage forms.
Caldolor can be used as management of mild to moderate pain, management of moderate to severe pain as an adjunct to opioid analgesics, reduction in fever through anti-inflammatory, analgesic, and antipyretic activity, methods of treating pain, inflammation and/or fever in a critically ill patient with intravenous ibuprofen in need thereof, management of mild to moderate pain, management of moderate to severe pain as an adjunct to opioid analgesics in a critically ill patient with intravenous ibuprofen in need thereof, methods of making aqueous composition and treating pain, inflammation, fever, patent ductus arteriosis with aqueous composition, methods of making aqueous composition and treating pain, inflammation, fever, patent ductus ateriosis with aqueous composition, methods of treating pain, inflammation, fever, patent ductus arteriosis with aqueous composition, methods of treating pain, inflammation and/or fever with intravenous ibuprofen such that mean arterial blood pressure does not increase the dosage interval.
The generics of Caldolor are possible to be released after 16 March, 2032.
| Drug Exclusivity | Drug Exclusivity Expiration |
|---|---|
| M(M-128) | Nov 19, 2024 |
| New Patient Population(NPP) | May 11, 2026 |
| New Product(NP) | Jun 11, 2012 |
| New Dosing Schedule(D-152) | Nov 20, 2018 |
Drugs and Companies using IBUPROFEN ingredient
Market Authorisation Date: 11 June, 2009
Treatment: Management of mild to moderate pain, management of moderate to severe pain as an adjunct to opioid analgesics, reduction in fever through anti-inflammatory, analgesic, and antipyretic activity; Manage...
Dosage: SOLUTION;INTRAVENOUS
CALDOLOR family patents
